Curevo Presents Positive Shingles Vaccine Outcomes Data
31 oct. 2024 02h00 HE
|
Curevo Vaccine
Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine
Curevo Vaccine Presents Amezosvatein Shingles Vaccine Data at ID Week
16 oct. 2024 11h00 HE
|
Curevo Vaccine
Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein elicits robust immune responses with better tolerability.
Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer
08 avr. 2024 10h00 HE
|
Curevo Vaccine
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved...
Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix
07 janv. 2024 11h00 HE
|
Curevo Vaccine
-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including...
Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare Conference
21 déc. 2023 08h00 HE
|
Curevo Vaccine
SEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...
Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer
11 avr. 2023 07h30 HE
|
Curevo Vaccine
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe...